D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Antigen dose and keratinocyte antigen presentation are specific determinants of T cell function in atopic eczema
Brian J Wallace,King-Bing Tan,Sarah Pett,Sarah Pett,David A. Cooper,David A. Cooper,Steven Kossard,Margot J Whitfeld +7 more
TL;DR: It is postulated that changes in DDC populations may contribute to the pathogenesis of the sclerotic process observed with enfuvirtide ISR.
Journal ArticleDOI
Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals
Amit C. Achhra,Janaki Amin,Caroline A. Sabin,Haitao Chu,David Dunn,Lewis H. Kuller,Joseph A. Kovacs,David A. Cooper,Sean Emery,Matthew Law +9 more
TL;DR: Risk reclassification provides a method for assessing the clinical utility of biomarkers in HIV cohort studies and appears to only modestly improve the discernment of risk in this relatively well population.
Journal ArticleDOI
Enfuvirtide in HIV-1-Infected Individuals Changing Therapy to A Nucleoside Reverse Transcriptase Inhibitor Sparing Regimen: The Alliance Study:
Dominic E. Dwyer,Cassy Workman,Gillian Hales,Janaki Amin,David A. Cooper,John Miller,Sean Emery +6 more
TL;DR: Enfuvirtide is an important component of antiretroviral therapy in highly treatment-experienced individuals where NRTI sparing may be desirable and was assessed in an open-label study of HIV-1-infected individuals.
Journal ArticleDOI
The future of cardiac xenotransplantation
TL;DR: The likely future of cardiac xenotransplantation is discussed, with initial clinical trials expected to explore compassionate use as destination therapy in carefully selected adult patients and as a bridge to heart allotrans transplantation in infant patients with complex congenital heart disease.
Journal ArticleDOI
The clinical characteristics of adults with rheumatic heart disease in Yangon, Myanmar: An observational study
Nan Phyu Sin Toe Myint,Ne Myo Aung,Myint Soe Win,Thu Ya Htut,Anna P. Ralph,David A. Cooper,Myo Lwin Nyein,Mar Mar Kyi,Josh Hanson,Josh Hanson +9 more
TL;DR: There is a significant and unmet clinical burden of RHD in Myanmar and a national RHD programme would improve patient care, reducing morbidity and mortality from this preventable disease.